C
C. A. Rask
Researcher at Genentech
Publications - 4
Citations - 750
C. A. Rask is an academic researcher from Genentech. The author has contributed to research in topics: Nerve growth factor & Nociception. The author has an hindex of 4, co-authored 4 publications receiving 725 citations.
Papers
More filters
Journal ArticleDOI
A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection
Justin C. McArthur,Constantin T. Yiannoutsos,David M. Simpson,Bruce T. Adornato,Elyse J. Singer,Harry Hollander,Camillo Marra,Michael Rubin,Bruce A. Cohen,Tarvez Tucker,Bradford A. Navia,Giovanni Schifitto,David Katzenstein,C. A. Rask,Lawrence Zaborski,Mary E. Smith,S. Shriver,Linda Millar,David B. Clifford +18 more
TL;DR: A positive effect of recombinant human nerve growth factor on neuropathic pain and pin sensitivity in HIV-associated sensory neuropathy was found and rhNGF was safe and well tolerated, but injection site pain was frequent.
Journal ArticleDOI
Intradermal recombinant human nerve growth factor induces pressure allodynia and lowered heat-pain threshold in humans
Peter James Dyck,S. Peroutka,C. A. Rask,E. Burton,M. K. Baker,K. A. Lehman,D. A. Gillen,J. L. Hokanson,P. C. O'Brien +8 more
TL;DR: The time course of pressure allodynia and heat-pain hyperalgesia is too rapid to be explained by uptake of NGF by nociception terminals, retrograde transport, and upregulation of pain modulators.
Journal ArticleDOI
Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. NGF Study Group.
TL;DR: In this article, the effects of recombinant human nerve growth factor in patients with diabetic polyneuropathy were evaluated and the results showed that it appeared to be safe and showed preliminary evidence of efficacy.
Journal Article
Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. authors' reply
J. E. Riggs,S. C. Apfel,W. J. Litchy,John A. Kessler,C. Sanders,Bruce T. Adornato,C. A. Rask +6 more
TL;DR: Recombinant human nerve growth factor appears to be safe and shows preliminary evidence of efficacy in patients with symptomatic diabetic polyneuropathy.